Oklo completed the acquisition of Atomic Alchemy, a radioisotope producer, for approximately $25 million, diversifying its business into medical and defense isotopes. The company reported a Q1 2026 net loss of $33.1 million, which was slightly worse than analysts' expectations. In the same quarter, Oklo's total operating expenses rose significantly from $52 million in the prior year to $139 million, indicating increased spending as it prepares for commercial production. Additionally, Oklo's free cash flow deteriorated sharply in Q3 2025, falling 188.8% to negative $23 million compared to the previous period, highlighting its worsening cash burn. Analysts projected a first-quarter loss of $0.18 per share, deeper than its year-ago quarterly loss of $0.07 per share, indicating a projected increase in net loss per share. Oklo also entered into a partnership with Meta Platforms, which could involve up to $2 billion in investments to develop advanced nuclear fuel fabrication infrastructure, and secured a major commercial agreement with Meta for a 1.2 GW nuclear power campus in Ohio, providing upfront capital to fund construction and early project development.